Prevention of breast cancer: Current state of the science and future opportunities

Expert Opinion on Investigational Drugs

Volumn 15, Issue 12, 2006, Pages 1583-1600

  Uray, Ivan P ^a   Brown, Powel H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemoprevention; Retiniod; SERM; Tamoxifen

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; BEXAROTENE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DESLORELIN; ESTRADIOL; EXEMESTANE; FENRETINIDE; FORMESTANE; GONADORELIN AGONIST; GOSERELIN; IDOXIFENE; LETROZOLE; LEUPRORELIN; LGD 100268; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RALOXIFENE; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; TRASTUZUMAB; UNINDEXED DRUG; VOROZOLE;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTHRITIS; BONE PAIN; BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; CAUSE OF DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FATIGUE; FRAGILITY FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GYNECOLOGIC DISEASE; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; HYSTERECTOMY; KIDNEY DISEASE; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH DISEASE; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; UTERUS CANCER; VAGINA BLEEDING; VAGINA DISCHARGE; VISUAL DISORDER; XEROSIS;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; FORECASTING; HUMANS; LEUPROLIDE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MIDDLE AGED; OVARIECTOMY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; RATS; RETINOIDS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 33845202059     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.12.1583     Document Type: Review

References (149)

1. CARTER CL, ALLEN C, HENSON DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer (1989) 63(1):181-187.
2. VELIE EM, SCHAIRER C, FLOOD A, HE JP, KHATTREE R, SCHATZKIN A: Empirically derived dietary patterns and risk of postmenopausal breast cancer in a large prospective cohort study. Am. J Clin. Nutr. (2005) 82(6):1308-1319.
3. CHEN WY, WILLETT WC, ROSNER B, COLDITZ CA: Moderate alcohol consumption and breast cancer risk. ASCO, Chicago, USA (2005):p7s.
4. DUMITRESCU RG, COTARLA I: Understanding breast cancer risk - where do we stand in 2005? J Cell Mol. Med. (2005) 9(1):208-221.
5. SUZUKI R, YE W, RYLANDER-RUDQVIST T, SAJI S, COLDITZ CA, WOLK A: Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl. Cancer Inst. (2005) 97(21):1601-1608.
6. BERNSTEIN L, PATEL AV, URSIN G et al.: Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl. Cancer Inst. (2005) 97(22):1671-1679.
7. HARTMANN LC, SCHAID DJ, WOODS JE et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. (1999) 340(2):77-84.
8. FROST MH, SCHAID DJ, SELLERS TA et al.: Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy.JAMA (2000) 284(3):319-324.
9. KIAN TEE M, ROGATSKY I, TZAGARAKIS-FOSTER C et al.: Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol. Biol. Cell (2004) 15(3):1262-1272.
10. FISHER B, JEONG JH, DIGNAM J et al.: Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl. Cancer Inst. Monogr. (2001) 30:62-66.
11. FISHER B, JEONG JH, BRYANT J et al.: Treatment of lymph-node-negative, oestrogen-recepror-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet (2004) 364(9437):858-868.
12. GROUP EBCTC: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet (1998) 351(9025):1451-1467.
13. GAIL MH, COSTANTINO JP, BRYANT J et al.: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl. Cancer Inst. (1999) 91(21):1829-1846.
14. WOLMARK N, DUNN BK: The role of tarnoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann. NY Acad. Sci. (2001) 949:99-108.
15. FISHER B, LAND S, MAMOUNAS E, DIGNAM J, FISHER ER, WOLMARK N: Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin. Oncol. (2001) 28(4):400-418.
16. FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (1998) 90(18):1371-1388.
17. POWLES T, EELES R, ASHLEY S et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 352(9122):98-101.
18. VERONESI U, MAISONNEUVE P, ROTMENSZ N et aL: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J. Natl. Cancer Inst. (2003) 95(2):160-165.
19. CUZICK J, FORBES J, EDWARDS R et al.: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 360(9336):817-824.
20. DUGGAN C, MARRIOTT K, EDWARDS R, CUZICK J: Inherited and acquired risk factors for venous thromboembotic disease among women taking tamoxifen to prevent breast cancer. J. Clin. Oncol. (2003) 21(19):3588-3593.
21. CUZICK J, POWLES T, VERONESI U et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 361(9354):296-300.
22. BLACK LJ, SATO M, ROWLEY ER et al.: Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. (1994) 93(1):63-69.
23. CUMMINGS SR, ECKERT S, KRUEGER KA et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA (1999) 281(23):2189-2197.
24. ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA (1999) 282(7):637-645.
25. DELMAS PD, ENSRUD KE, ADACHI JD et al.: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. (2002) 87(8):3609-3617.
26. COX DA, SARKAR S, HARPER K, BARRETT-CONNOR E: Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. Curr. Med. Res. Opin. (2004) 20(7):1049-1055.
27. DICKLER MN, NORTON L: The MORE trial: multiple outcomes for raloxifene evaluation - breast cancer as a secondary end point: implications for prevention. Ann. NY Acad. Sci. (2001) 949:134-142.
28. CAULEY JA, NORTON L, LIPPMAN ME et al.: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res. Treat. (2001) 65(2):125-134.
29. DOWSETT M, BUNDRED NJ, DECENSI A et al.: Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol. Biomarkers Prev. (2001) 10(9):961-966.
30. BLUMENTHAL RS, BAKANOWSKI B, DOWSETT SA: Cardiovascular effects of raloxifene: the arterial and venous systems. Am. Heart J (2004) 147(5):783-789.
31. MERCHENTHALER I, FUNKHOUSER JM, CARVER JM, LUNDEEN SG, GHOSH K, WINNEKER RC: The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas (1998) 30(3):307-316.
32. MARTINO S, CAULEY JA, BARRETT-CONNOR E et al.: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. (2004) 96(23):1751-1761.
33. SIRIS ES, HARRIS ST, EASTELL R et al.: Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) Study. J. Bone Miner. Res. (2005) 20(9):1514-1524.
34. SUH N, GLASEBROOK AL, PALKOWITZ AD et al.: Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. (2001) 61(23):8412-8415.
35. SUH N, LAMPH WW, GLASEBROOK AL et al.: Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin. Cancer Res. (2002) 8(10):3270-3275.
36. RENDI MH, SUH N, LAMPH WW et al.: The selective estrogen receptor modulator arzoxifene and the rexinoid LG 100268 cooperate to promote transforming growth factor β-dependent apoptosis in breast cancer. Cancer Res. (2004) 64(10):3566-3571.
37. FABIAN CJ, KIMLER BF, ANDERSON J et al.: Breast cancer chemoprevention Phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin. Cancer Res. (2004) 10(16):5403-5417.
38. SANTEN RJ: Clinical use of aromatase inhibitors in human breast carcinoma. J. Steroid Biochem. Mol. Biol. (1991) 40(1-3):247-253.
39. GEISLER J, KING N, ANKER G et al.: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. (1998) 4(9):2089-2093.
40. MOON RC, STEELE VE, KELLOFF GJ et al.: Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anti-Cancer Res. (1994) 14(3A):889-893.
41. LUBET RA, STEELE VE, CASEBOLT TL, ETO I, KELLOFF GJ, GRUBBS CJ: Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis (1994) 15(12):2775-2780.
42. LU Q, YUE W. WANG J, LIU Y, LONG B, BRODIE A: The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res. Treat. (1998) 50(1):63-71.
43. BUZDAR AU: Endocrine therapy in the treatment of metastatic breast cancer. Semin. Oncol. (2001) 28(3):291-304.
44. COHEN MH, JOHNSON JR, LI N, CHEN G, PAZDUR R: Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Clin. Cancer Res. (2002) 8(3):665-669.
45. COOMBES RC, GIBSON L, HALL E, EMSON M, BLISS J: Aromatase inhibitors as adjuvant therapies in patients with breast cancer. J. Steroid Biochem. Mol, Biol. (2003) 86(3-5):309-311.
46. DANK M: The role of aromasin in the hormonal therapy of breast cancer. Pathol. Oncol. Res. (2002) 8(2):87-92.
47. MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. (2001) 19(10):2596-2606.
48. BUZDAR AU, CUZICK J: Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin. Cancer Res. (2006) 12(3 Part 2):1037s- 1048s.
49. HOWELL A, CUZICK J, BAUM M et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 365(9453):60-62.
50. NABHOLTZ JM: Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention. Oncology (2006) 70(1):1-12.
51. COOMBES RC, HALL E, GIBSON LJ et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. (2004) 35(11):1081-1092.
52. GOSS PE, INGLE JN, MARTINO S et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J. Natl. Cancer Inst. (2005) 97(17):1262-1271.
53. CUZICK J: Aromatase inhibitors in prevention-data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res. (2003) 163:96-103 (Discussion 264-106).
54. INGLE JN: Endocrine therapy trials of aromarase inhibitors for breast cancer in the adjuvant and prevention settings. Clin. Cancer Res. (2005) 11(2 Part 2):900s-905s.
55. GOSS PE, INGLE JN, MARTINO S et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. (2003) 349(19):1793-1802.
56. GOSS PE, QI S, JOSSE RG et al.: The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone (2004) 34(3):384-392.
57. MOKBEL K: Risk-reducing strategies for breast cancer-a review of recent literature. Int. J. Fertil. Womens Med. (2003) 48(6):274-277.
58. PIKE MC, ROSS RK, LOBO RA, KEY TJ, POTTS M, HENDERSON BE: LHRH agonists and the prevention of breast and ovarian cancer. Br. J. Cancer (1989) 60(1):142-148.
59. HOLLINGSWORTH AB, LERNER MR, LIGHTFOOT SA et al.: Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen. Breast Cancer Res. Treat. (1998) 47(1):63-70.
60. GRAM IT, URSIN G, SPICER DV, PIKE MC: Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol. Biomarkers. Prev. (2001) 10(11):1117-1120.
61. SPICER DV, PIKE MC: Future possibilities in the prevention of breast cancer: luteinizing hormone-releasing hormone agonists. Breast Cancer Res. (2000) 2(4):264-267.
62. SZANTO A, NARKAR V, SHEN Q, URAY IP, DAVIES PJ, NAGY L: Retinoid X receptors: X-ploring their (patho) physiological functions. Cell Death Differ. (2004) 11(Suppl. 2):S126-S143.
63. YANG L, OSTROWSKI J, RECZEK P. BROWN P: The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFβ and causing cell cycle arrest. Oncogene (2001) 20(55):8025-8035.
64. SHANG Y, BAUMRUCKER CR, GREEN MH: Signal relay by retinoic acid receptors α and β in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells. J. Biol. Chem. (1999) 274(25):18005-18010.
65. LIU Y, LEE MO, WANG HG et al: Retinoic acid receptor β mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. (1996) 16(3):1138-1149.
66. KONG G, KIM HT, WU K et al.: The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. (2005) 65(8):3462-3469.
67. MANGELSDORF DJ, ONG ES, DYCK JA, EVANS RM: Nuclear receptor that identifies a novel retinoic acid response pathway. Nature (1990) 345(6272):224-229.
68. HEYMAN RA, MANGELSDORF DJ, DYCK JA et al.: 9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell (1992) 68(2):397-406.
69. MOON RC, CONSTANTINOU AI: Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res. Treat. (1997) 46(2-3):181-189.
70. MOON RC, THOMPSON HJ, BECCI PJ et al.: N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. (1979) 39(4):1339-1346.
71. WU K, KIM HT, RODRIQUEZ JL et al.: 9-Cis-retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin. Cancer Res. (2000) 6(9):3696-3704.
72. ANZANO MA, BYERS SW, SMITH JM et al.: Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. (1994) 54(17):4614-4617.
73. BISCHOFF ED, HEYMAN RA, LAMPH WW: Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J. Natl. Cancer Inst. (1999) 91(24):2118.
74. WU K, KIM HT, RODRIQUEZ JL et al.: Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol. Biomarkers Prev. (2002) 11(5):467-474.
75. WU K, ZHANG Y, XU XC et al.: The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. (2002) 62(22):6376-6380.
76. FRANKEL SR, POWELL BL: Current approaches to acute promyelocytic leukemia. Cancer Treat. Res. (1999) 99:125-153.
77. 2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J. Natl. Cancer Inst. (1992) 84(4):241-245.
78. COHEN MH, HIRSCHFELD S, FLAMM HONIG S et al.: Drug approval summaries: arsenic trioxide, tamoxifen citrate, anasurazole, paclitaxel, bexarotene. Oncologist (2001) 6(1):4-11.
79. HONG WK, LIPPMAN SM, ITRI LM et al.: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med (1990) 323(12):795-801.
80. COSTA A, FORMELLI F, CHIESA F, DECENSI A, DE PALO G, VERONESI U: Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. (1994) 54(Suppl. 7):2032s-2037s.
81. VERONESI U, DE PALO G, MARUBINI E et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. (1999) 91(21):1847-1856.
82. DECENSI A, BONANNI B, GUERRIERI-GONZAGA A et al.: Chemoprevention of breast cancer: the Italian experience. J. Cell. Biochem. (2000) 77(S34):84-96.
83. TORRISI R, DECENSI A, FORMELLI F, CAMERINI T, DE PALO G: Chemoprevention of breast cancer with fenretinide. Drugs (2001) 61(7):909-918.
84. SINGLETARY SE, ATKINSON EN, HOQUE A et al.: Phase II clinical trial of N-(4-hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoptasia. Clin. Cancer Res. (2002) 8(9):2835-2842.
85. GARAVFNTA A, LUKSCH R, LO PICCOLO MS et al.: Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin. Cancer Res. (2003) 9(6):2032-2039.
86. HARRIS RE, BEEBE-DONK J, DOSS H, BURR DOSS D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol. Rep. (2005) 13(4):559-583.
87. MORAN EM: Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J. Environ. Pathol. Toxicol. Oncol. (2002) 21(2):193-201.
88. WADDELL WR, GANSER GF, CERISE EJ, LOUGHRY RW. Sulindac for polyposis of the colon. Am. J. Surg. (1989) 157(1):175-179.
89. THUN MJ, NAMBOODIRI MM, CALLE EE, FLANDERS WD, HEATH CW Jr: Aspirin use and risk of fatal cancer. Cancer Res. (1993) 53(6):1322-1327.
90. HARRIS RE, NAMBOODIRI K, STELLMAN SD, WYNDER EL: Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev. Med. (1995) 24(2):119-120.
91. SCHREINEMACHERS DM, EVERSON RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology (1994) 5(2):138-146.
92. RAHME E, GHOSN J, DASGUPTA K, RAJAN R, HUDSON M: Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer (2005) 5:159.
93. JACOBS EJ, THUN MJ, CONNELL CJ et al.: Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large US cohort. Cancer Epidemiol. Biomarkers Prev. (2005) 14(1):261-264.
94. EGAN KM, STAMPTER MJ, GIOVANNUCCI E, ROSNER BA, COLDITZ GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl. Cancer Inst. (1996) 88(14):988-993.
95. HARRIS RE, NAMBOODIRI KK, FARRAR WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology (1996) 7(2):203-205.
96. TERRY MB, GAMMON MD, ZHANG FF et al.: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 291(20):2433-2440.
97. HARRIS RE, BEEBE-DONK J, ALSHAFIE GA: Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer (2006) 6:27.
98. WARNER TD, MITCHELL JA: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J (2004) 18(7):790-804.
99. HOWE LR, DANNENBERG AJ: COX-2 inhibitors for the prevention of breast cancer. J. Mammary Gland Biol. Neoplasia (2003) 8(1):31-43.
100. HALF E, TANG XM, GWYN K, SAHIN A, WATHEN K, SINICROPE FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. (2002) 62(6):1676-1681.
101. RISTIMAKI A, SIVULA A, LUNDIN J et al.: Prognostic significance of elevated cyclaoxygenase-2 expression in breast cancer. Cancer Res. (2002) 62(3):632-635.
102. EDWARDS J, MUKHERJEE, R, MUNRO AF, WELLS AC, ALMUSHATAT A, BARTLETT JM: HER2 and COX2 expression in human prostate cancer. Eur. J. Cancer (2004) 40(1):50-55.
103. RANGER GS, JEWELL A, THOMAS V, MOKBEL K: Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J. Surg. Oncol (2004) 88(2):100-103.
104. 2-dependent angiogenic switch in cyclooxygenase 2- induced breast cancer progression. Proc Nad. Acad Sci. USA (2004) 101(2):591-596.
105. BRUEGGEMEIER RW, RICHARDS JA, JOOMPRABUTRA S, BHAT AS, WHETSTONE JL: Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. J Steroid Biochem. Mol. Biol. (2001) 79(1-5):75-84.
106. DIAZ-CRUZ ES, SHAPIRO CL, BRUEGGEMEIER RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J. Clin. Endocrinol. Metab. (2005) 90(5):2563-2570.
107. LIU CH, CHANG SH, NARKO K et al.: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Cbem. (2001) 276(21):18563-18569.
108. HARRIS RE, ALSHAFIE GA, ABOU-ISSA H, SEIBERT K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. (2000) 60(8):2101-2103.
109. HOWE LR, SUBBARAMAIAH K, PATEL J et al: Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. (2002) 62(19):5405-5407.
110. LANZA-JACOBY S, MILLER S, FLYNN J et al: The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol. Biomarkers Prev. (2003) 12(12):1486-1491.
111. SUBHASHINI J, MAHIPAL SV, REDDANNA P: Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett. (2005) 224(1):31-43.
112. LEE TK, STUPANS I: Radioprorection: the non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins. J. Pharm. Pharmacol. (2002) 54(11):1435-1445.
113. STEINBACH G, LYNCH PM, PHILLIPS RK et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. (2000) 342(26):1946-1952.
114. SUBBARAMAIAH K, DANNENBERG AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pbarmacol, Sci. (2003) 24(2):96-102.
115. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343(21):1520-1528 (2 p following 1528).
116. SOLOMON SD, McMURRAY JJ, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorecral adenoma prevention. N. Engl. J. Med. (2005) 352(11):1071-1080.
117. BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. (2005) 352(11):1092-1102.
118. ARIGA R, ZARIF A, KORASICK J, REDDY V, SIZIOPIKOU K, GATTUS0 P: Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J. (2005) 11(4):278-280.
119. SALH B, MAROTTA A, MATTHEWSON C et al.: Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anti-Cancer Res. (1999) 19(1B):731-740.
120. EMENS LA, DAVIDSON NE: Trastuzumab in breast cancer. Oncology (Williston Park) (2004) 18(9):1117-1128 (Discussion 1131-1112, 1137-1118).
121. PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al: Trasruzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
122. KIM ES: Cetuximab as a single agent or in combination with chemotherapy in lung cancer. Clin. Lung Cancer (2004) 6(Suppl. 2):S80-S84.
123. VAN DER HORST EH, MURGIA M, TREDER M, ULLRICH A: Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. Int. J. Cancer (2005) 115(4):519-527.
124. KUWADA SK, SCAIFE CL, KUANG J et al.: Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int. J. Cancer (2004) 109(2):291-301.
125. FRIESS T, SCHEUER W, HASMANN M: Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin. Cancer Res. (2005) 11(14):5300-5309.
126. BURRIS HA III, HURWITZ HI, DEES EC et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016): a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. (2005) 23(23):5305-5313.
127. SAWYERS CL, HOCHHAUS A, FELDMAN E et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99(10):3530-3539.
128. SAVAGE DG, ANTMAN KH: Imatinib mesylate - a new oral targeted therapy. N. Engl. J. Med. (2002) 346(9):683-693.
129. BOSCHELLI DH: 4-Anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors. Curr. Top. Med. Chem. (2002) 2(9):1051-1063.
130. GRUNWALD V, HIDALGO M: Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv. Exp. Med. Biol. (2003) 532:235-246.
131. ZHOU Y, BRATTAIN MG: Synergy of epidermal growth factor receptor kinase inhibitor AG 1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. Cancer Res. (2005) 65(13):5848-5856.
132. MELLINGHOFF IK, TRAN C, SAWYERS CL: Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. (2002) 62(18):5254-5259.
133. COHEN MH, WILLIAMS GA, SRIDHARA R et al: United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. (2004) 10(4):1212-1218.
134. TWOMBLY R: Failing survival advantage in crucial trial, future of Iressa is in jeopardy. J. Natl. Cancer Inst. (2005) 97(4):249-250.
135. TANG PA, TSAO MS, MOORE MJ: A review of erlotinib and its clinical use. Expert Opin. Pbarmacother. (2006) 7(2):177-193.
136. YANG Z, BAGHERI-YARMAND R, WANG RA et al.: The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin. Cancer Res. (2004) 10(2):658-667.
137. YANASE K, TSUKAHARA S, ASADA S, ISHIKAWA E, IMAI Y, SUGIMOTO Y: Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther. (2004) 3(9):1119-1125.
138. CIARDIELLO F, CAPUTO R, BIANCO R et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa): a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. (2001) 7(5):1459-1465.
139. WAKELING AE, GUY SP, WOODBURN JR et al.: ZD 1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. (2002) 62(20):5749-5754.
140. SIROTNAK FM, ZAKOWSKI MF, MILLER VA, SCHER HI, KRIS MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa): an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. (2000) 6(12):4885-4892.
141. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350(21):2129-2139.
142. LU C, SPEERS C, ZHANG Y et al.: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.J. Natl. Cancer Inst. (2003) 95(24):1825-1833.
143. CHAN KC, KNOX WF, GANDHI A, SLAMON DJ, POTTEN CS, BUNDRED NJ: Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br. J. Surg. (2001) 88(3):412-418.
144. FUSTER LM, SANDLER AB: Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on Phase III outcomes. Clin. Lung Cancer (2004) 6(Suppl. 1):S24-S29.
145. XIA W, MULLIN RJ, KEITH BR et al.: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21(41):6255-6263.
146. XIA W, GERARD CM, LIU L, BAUDSON NM, ORY TL, SPECTOR NL: Combining lapatinib (GW572016): a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene (2005) 24(41):6213-6221.
147. BENCE AK, ANDERSON EB, HALEPOTA MA et al.: Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest. New Drugs (2005) 23 (1):39-49.
148. BRODIE AM, LU Q, LONG BJ et al.: Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem. Mol. Biol. (2001) 79(1-5):41-47.
149. GOSS PE, STRASSER-WEIPPL K: Prevention strategies with aromatase inhibitors. Clin. Cancer Res. (2004) 10(I Part 2):372S-379S.